Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$2.92
+2.5%
$2.52
$1.97
$12.00
$13.04M0.26721,695 shs9,339 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.10
-4.3%
$1.15
$0.95
$5.99
$13.01M1.2963,562 shs48,971 shs
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$6.52
-3.3%
$5.30
$2.12
$12.72
$12.26M0.26350,730 shs17,496 shs
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$1.80
-2.2%
$2.21
$1.71
$20.28
$3.18M4.33163,347 shs12,962 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-1.48%-0.34%+11.03%-0.68%-41.21%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-4.35%0.00%-12.70%-27.87%-72.01%
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-3.26%+17.90%+20.96%+25.63%+651,999,900.00%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
-2.17%-5.26%-17.05%-50.00%-99.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
2.597 of 5 stars
0.05.00.00.03.83.30.6
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
4.0276 of 5 stars
3.83.00.03.92.50.80.6
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
1.5512 of 5 stars
3.50.00.00.02.00.00.6
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
0.3142 of 5 stars
0.02.00.00.02.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00
N/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.171,096.97% Upside
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
3.00
Buy$21.00222.09% Upside
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RDHL, LIPO, MRKR, and NEUP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50
3/5/2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$536.36K24.32N/AN/A$4.33 per share0.67
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M1.89N/AN/A$1.58 per share0.70
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$15.66M0.78N/AN/A$7.82 per share0.83
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$8.04M0.40$180.00 per share0.01$40.58 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$4.62M-$4.08N/AN/A-882.82%-192.33%-154.24%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$8.24M-$1.33N/AN/AN/A-179.74%-89.63%-71.62%8/13/2025 (Estimated)
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$15.49MN/A0.00N/AN/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$23.92MN/A0.00N/AN/AN/AN/A6/14/2025 (Estimated)

Latest RDHL, LIPO, MRKR, and NEUP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q3 2025
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$0.47$6.55+$7.02$6.55N/A$15.00 million
5/14/2025Q1 2025
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A-$0.64N/A-$0.64N/A$0.13 million
3/31/2025Q4 2024
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million
3/27/2025Q4 2024
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$2.43-$1.19+$1.24-$1.19N/A$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A
2.97
2.97
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
3.15
3.15
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A
2.06
3.30
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/A
0.74
0.56
CompanyEmployeesShares OutstandingFree FloatOptionable
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
44.47 million821,000Not Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.32 million9.16 millionNot Optionable
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A1.88 million1.75 millionN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
2101.77 million1.19 millionNo Data

Recent News About These Companies

RedHill Biopharma receives non-compliance letter from Nasdaq
RedHill Biopharma announces publication in journal on Opaganib
RedHill Biopharma to submit UK MAA for Talicia
RedHill to file FDA-approved Talicia for UK marketing
RedHill Licenses RHB-102 to Hyloris

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lipella Pharmaceuticals stock logo

Lipella Pharmaceuticals NASDAQ:LIPO

$2.92 +0.07 (+2.46%)
Closing price 05/28/2025 03:58 PM Eastern
Extended Trading
$2.99 +0.07 (+2.40%)
As of 05/28/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.10 -0.05 (-4.35%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.00 (+0.09%)
As of 05/28/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Neuphoria Therapeutics Inc. - Common Stock stock logo

Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP

$6.52 -0.22 (-3.26%)
As of 05/28/2025 03:51 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

RedHill Biopharma stock logo

RedHill Biopharma NASDAQ:RDHL

$1.80 -0.04 (-2.17%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$1.79 -0.01 (-0.33%)
As of 05/28/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.